PDCD1 and neoplasm: Since the number of tumor cells that express PD-L1 largely affects its ability to suppress immunogenicity and further determine the effectiveness of PD-L1 and PD-1 blockage by ICI, the expression of PD-L1 on tumor cells is a predictive biomarker for ICI therapy.